clinical trial · NCT06754852
A Study Assessing HMB-002 in Participants With Von Willebrand Disease
Von Willebrand Disease (VWD)Von Willebrand Disease (VWD), Type 1Von Willebrand Disease (VWD), Type 2HMB-002 (Part A)HMB-002 (Part B)
brief summary
This is a first-in-human (FIH), Phase 1/2, open-label, dose escalation, safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and efficacy study of HMB-002 in participants with VWD. Part A of the study involves a single ascending dose (SAD) design to establish safety, tolerability, PK, and PD effect. In Part B of the study, the safety and tolerability of repeat dosing will be established prior to cohort expansion to explore efficacy.
started
Feb 6, 2025
primary completion
Jul 1, 2027
completion
Jul 1, 2027
last updated
Dec 9, 2025
official title
A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-002 in Participants With Von Willebrand Disease (Velora Pioneer)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol